Tag Archives: Combination

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Which Drug Combination Works Best to Reduce Acute COPD Exacerbations?

November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »

FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a… Read More »